Biologic Medications: A Whole New World
Price: FREE for members and non-members
Session recorded on June 18, 2020
Speaker: John Oppenheimer, MD
Viewers can earn credit by completing the posttest questions
This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.
There is no commercial support for this activity.
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Upon completion of this webinar, the participant should be able to:
- Recognize the heterogeneity of asthma and the appropriate use of biologic agents in this illness
- Recognize the subtypes of chronic sinusitis and the appropriate use of biologic agents in chronic sinusitis with nasal polyposis
- Improve understanding of the heterogeneity of asthma and chronic sinusitis
All identified conflicts of interest have been resolved.
Sally Schlosser, RN, Planner, Reviewer
Nothing to disclose
Michael Blaiss, MD, Planner
Disclosures: Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
John Oppenheimer, MD, Speaker
Disclosures: Consultant/Consulting fee: AZ, GSK, Novartis and Sanofi
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance